The company is the only biopharma focused exclusively on the development and commercialisation of new treatment options for people with hemophilia.
Butler has more than 20 years experience in the field of commercialisation for innovative therapies.
He replaces Michael Griffith, who will become chief scientific officer, and will remain as president at Inspiration.
New appointments at biopharma and equipment companies also feature in this week's column.
Plus other people on the move in the pharma industry in this week's column.
People are on the move at Baxter, Merck & Co., Johnson & Johnson, and elsewhere in this...
Twin changes at AstraZeneca's MedImmune kick off this week's gallery, as well as jobs news from Europe
UCB has more than drugs in its 2015 pipeline, while BUPA and biotechs hire new recruits.